EXOSENS SAS (EXENS.PA) Stock Fundamental Analysis

EPA:EXENS • FR001400Q9V2

59.5 EUR
+0.9 (+1.54%)
Last: Feb 25, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

Overall EXENS gets a fundamental rating of 5 out of 10. We evaluated EXENS against 51 industry peers in the Aerospace & Defense industry. EXENS has an excellent financial health rating, but there are some minor concerns on its profitability. EXENS shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year EXENS was profitable.
  • In the past year EXENS had a positive cash flow from operations.
EXENS.PA Yearly Net Income VS EBIT VS OCF VS FCFEXENS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 50M -50M -100M

1.2 Ratios

  • The Return On Assets of EXENS (3.54%) is comparable to the rest of the industry.
  • The Return On Equity of EXENS (7.14%) is worse than 64.71% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 7.97%, EXENS is in line with its industry, outperforming 56.86% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for EXENS is below the industry average of 9.44%.
  • The 3 year average ROIC (7.01%) for EXENS is below the current ROIC(7.97%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 3.54%
ROE 7.14%
ROIC 7.97%
ROA(3y)2.89%
ROA(5y)N/A
ROE(3y)7.53%
ROE(5y)N/A
ROIC(3y)7.01%
ROIC(5y)N/A
EXENS.PA Yearly ROA, ROE, ROICEXENS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

  • Looking at the Profit Margin, with a value of 7.79%, EXENS is in the better half of the industry, outperforming 72.55% of the companies in the same industry.
  • With an excellent Operating Margin value of 18.28%, EXENS belongs to the best of the industry, outperforming 94.12% of the companies in the same industry.
  • EXENS's Gross Margin of 73.86% is amongst the best of the industry. EXENS outperforms 96.08% of its industry peers.
  • EXENS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 18.28%
PM (TTM) 7.79%
GM 73.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.14%
GM growth 5YN/A
EXENS.PA Yearly Profit, Operating, Gross MarginsEXENS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • EXENS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • EXENS has less shares outstanding than it did 1 year ago.
  • EXENS has a better debt/assets ratio than last year.
EXENS.PA Yearly Shares OutstandingEXENS.PA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 100M 200M 300M
EXENS.PA Yearly Total Debt VS Total AssetsEXENS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 5.19 indicates that EXENS is not in any danger for bankruptcy at the moment.
  • EXENS has a Altman-Z score of 5.19. This is amongst the best in the industry. EXENS outperforms 84.31% of its industry peers.
  • The Debt to FCF ratio of EXENS is 4.73, which is a neutral value as it means it would take EXENS, 4.73 years of fcf income to pay off all of its debts.
  • EXENS's Debt to FCF ratio of 4.73 is fine compared to the rest of the industry. EXENS outperforms 62.75% of its industry peers.
  • EXENS has a Debt/Equity ratio of 0.61. This is a neutral value indicating EXENS is somewhat dependend on debt financing.
  • EXENS has a worse Debt to Equity ratio (0.61) than 64.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 4.73
Altman-Z 5.19
ROIC/WACC0.88
WACC9.04%
EXENS.PA Yearly LT Debt VS Equity VS FCFEXENS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 100M 200M 300M 400M

2.3 Liquidity

  • EXENS has a Current Ratio of 2.51. This indicates that EXENS is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 2.51, EXENS belongs to the top of the industry, outperforming 90.20% of the companies in the same industry.
  • A Quick Ratio of 1.67 indicates that EXENS should not have too much problems paying its short term obligations.
  • The Quick ratio of EXENS (1.67) is better than 90.20% of its industry peers.
Industry RankSector Rank
Current Ratio 2.51
Quick Ratio 1.67
EXENS.PA Yearly Current Assets VS Current LiabilitesEXENS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • EXENS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 102.95%, which is quite impressive.
  • EXENS shows a strong growth in Revenue. In the last year, the Revenue has grown by 35.04%.
  • Measured over the past years, EXENS shows a very strong growth in Revenue. The Revenue has been growing by 33.36% on average per year.
EPS 1Y (TTM)102.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%875.18%
Revenue 1Y (TTM)35.04%
Revenue growth 3Y33.36%
Revenue growth 5YN/A
Sales Q2Q%20.13%

3.2 Future

  • EXENS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.28% yearly.
  • EXENS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.19% yearly.
EPS Next Y52.91%
EPS Next 2Y37.16%
EPS Next 3Y30.01%
EPS Next 5Y23.28%
Revenue Next Year17.84%
Revenue Next 2Y16.17%
Revenue Next 3Y14.56%
Revenue Next 5Y12.19%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EXENS.PA Yearly Revenue VS EstimatesEXENS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
EXENS.PA Yearly EPS VS EstimatesEXENS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5 2 2.5

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 80.41, EXENS can be considered very expensive at the moment.
  • Based on the Price/Earnings ratio, EXENS is valued a bit more expensive than the industry average as 64.71% of the companies are valued more cheaply.
  • The average S&P500 Price/Earnings ratio is at 27.05. EXENS is valued rather expensively when compared to this.
  • The Price/Forward Earnings ratio is 31.93, which means the current valuation is very expensive for EXENS.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of EXENS is on the same level as its industry peers.
  • EXENS is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 28.03, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 80.41
Fwd PE 31.93
EXENS.PA Price Earnings VS Forward Price EarningsEXENS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

  • 60.78% of the companies in the same industry are cheaper than EXENS, based on the Enterprise Value to EBITDA ratio.
  • EXENS's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 53.55
EV/EBITDA 27.66
EXENS.PA Per share dataEXENS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • EXENS's earnings are expected to grow with 30.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.52
PEG (5Y)N/A
EPS Next 2Y37.16%
EPS Next 3Y30.01%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

1

5. Dividend

5.1 Amount

  • EXENS has a yearly dividend return of 0.17%, which is pretty low.
  • EXENS's Dividend Yield is slightly below the industry average, which is at 0.76.
  • With a Dividend Yield of 0.17, EXENS pays less dividend than the S&P500 average, which is at 1.80.
Industry RankSector Rank
Dividend Yield 0.17%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
EXENS.PA Yearly Dividends per shareEXENS.PA Yearly Dividends per shareYearly Dividends per share 2025 0.02 0.04 0.06 0.08

5.3 Sustainability

DPN/A
EPS Next 2Y37.16%
EPS Next 3Y30.01%
EXENS.PA Yearly Income VS Free CF VS DividendEXENS.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2021 2022 2023 2024 0 50M -50M -100M

More info and screens

Find the best dividend stocksShow peers with best dividend

EXOSENS SAS

EPA:EXENS (2/25/2026, 7:00:00 PM)

59.5

+0.9 (+1.54%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryAerospace & Defense
Earnings (Last)10-27
Earnings (Next)02-23
Inst Owners47.67%
Inst Owner ChangeN/A
Ins Owners1.86%
Ins Owner ChangeN/A
Market Cap3.03B
Revenue(TTM)394.08M
Net Income(TTM)30.68M
Analysts78.89
Price Target52.04 (-12.54%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.17%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.55%
PT rev (3m)6.3%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-1.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.1%
Revenue NY rev (3m)-1.19%
Valuation
Industry RankSector Rank
PE 80.41
Fwd PE 31.93
P/S 7.69
P/FCF 53.55
P/OCF 30.11
P/B 7.06
P/tB N/A
EV/EBITDA 27.66
EPS(TTM)0.74
EY1.24%
EPS(NY)1.86
Fwd EY3.13%
FCF(TTM)1.11
FCFY1.87%
OCF(TTM)1.98
OCFY3.32%
SpS7.74
BVpS8.43
TBVpS-0.02
PEG (NY)1.52
PEG (5Y)N/A
Graham Number11.85
Profitability
Industry RankSector Rank
ROA 3.54%
ROE 7.14%
ROCE 9.7%
ROIC 7.97%
ROICexc 9.07%
ROICexgc 26.62%
OM 18.28%
PM (TTM) 7.79%
GM 73.86%
FCFM 14.36%
ROA(3y)2.89%
ROA(5y)N/A
ROE(3y)7.53%
ROE(5y)N/A
ROIC(3y)7.01%
ROIC(5y)N/A
ROICexc(3y)7.64%
ROICexc(5y)N/A
ROICexgc(3y)25.3%
ROICexgc(5y)N/A
ROCE(3y)8.53%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.14%
GM growth 5YN/A
F-Score6
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.61
Debt/FCF 4.73
Debt/EBITDA 2.3
Cap/Depr 104.13%
Cap/Sales 11.18%
Interest Coverage 250
Cash Conversion 88.02%
Profit Quality 184.49%
Current Ratio 2.51
Quick Ratio 1.67
Altman-Z 5.19
F-Score6
WACC9.04%
ROIC/WACC0.88
Cap/Depr(3y)105.99%
Cap/Depr(5y)N/A
Cap/Sales(3y)10.64%
Cap/Sales(5y)N/A
Profit Quality(3y)171.48%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)102.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%875.18%
EPS Next Y52.91%
EPS Next 2Y37.16%
EPS Next 3Y30.01%
EPS Next 5Y23.28%
Revenue 1Y (TTM)35.04%
Revenue growth 3Y33.36%
Revenue growth 5YN/A
Sales Q2Q%20.13%
Revenue Next Year17.84%
Revenue Next 2Y16.17%
Revenue Next 3Y14.56%
Revenue Next 5Y12.19%
EBIT growth 1Y45.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year76.83%
EBIT Next 3Y32.9%
EBIT Next 5Y24.51%
FCF growth 1Y181.68%
FCF growth 3Y33.59%
FCF growth 5YN/A
OCF growth 1Y90.75%
OCF growth 3Y31.16%
OCF growth 5YN/A

EXOSENS SAS / EXENS.PA FAQ

What is the fundamental rating for EXENS stock?

ChartMill assigns a fundamental rating of 5 / 10 to EXENS.PA.


What is the valuation status for EXENS stock?

ChartMill assigns a valuation rating of 2 / 10 to EXOSENS SAS (EXENS.PA). This can be considered as Overvalued.


Can you provide the profitability details for EXOSENS SAS?

EXOSENS SAS (EXENS.PA) has a profitability rating of 4 / 10.


How financially healthy is EXOSENS SAS?

The financial health rating of EXOSENS SAS (EXENS.PA) is 7 / 10.


What is the expected EPS growth for EXOSENS SAS (EXENS.PA) stock?

The Earnings per Share (EPS) of EXOSENS SAS (EXENS.PA) is expected to grow by 52.91% in the next year.